Lipid-lowering therapy in HIV-infected patients: Relationship with antiretroviral agents and impact of substance-related disorders

Cindy Bednasz, Amneris E. Luque, Barry S. Zingman, Margaret A. Fischl, Barbara M. Gripshover, Charles S. Venuto, Jie Gu, Zekun Feng, Robin DiFrancesco, Gene D. Morse, Qing Ma

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: The use of combination antiretroviral therapy (cART) has significantly decreased the morbidity and mortality associated with human immunodeficiency virus (HIV) infection. Lipid disorders, including lipodystrophy, hypertriglyceridemia, and hypercholesterolemia, remain the most commonly reported metabolic disorders among those treated with long-term cART. Mounting evidence suggests an association between drug abuse and poor glycemic control and diabetes complications. Substance related disorders (SRD) may increase the risk of metabolic syndrome. Materials and Methods: The aim of this retrospective cohort study was to examine the relationship between SRD, cART, and lipid-lowering agent use in an HIV infected population. Patients received efavirenz or protease inhibitor-based cART for at least 6 months. Prescription information was retrieved from the medical records. The primary outcome was the use of lipid-lowering agents including statins, fibrates and fish oil. The impact of SRD and cART was assessed on the lipidlowering agent use. Results: A total of 276 subjects with HIV infection were included, 90 (33%) received lipid-lowering agents, and 31 (34%) had SRD. Smoking was prevalent among subjects with SRD (84 vs 15%, p

Original languageEnglish (US)
Pages (from-to)280-287
Number of pages8
JournalCurrent Vascular Pharmacology
Volume14
Issue number3
StatePublished - May 1 2016

Fingerprint

Anti-Retroviral Agents
Substance-Related Disorders
HIV
Lipids
efavirenz
Virus Diseases
Therapeutics
Lipodystrophy
Fibric Acids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Fish Oils
Hypertriglyceridemia
Diabetes Complications
Hypercholesterolemia
Protease Inhibitors
Medical Records
Prescriptions
Cohort Studies
Retrospective Studies
Smoking

Keywords

  • Dyslipidemia
  • Fibrates
  • HIV
  • Lipid-lowering therapy
  • Metabolic disorder
  • Statins
  • Substance-related disorders

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Lipid-lowering therapy in HIV-infected patients : Relationship with antiretroviral agents and impact of substance-related disorders. / Bednasz, Cindy; Luque, Amneris E.; Zingman, Barry S.; Fischl, Margaret A.; Gripshover, Barbara M.; Venuto, Charles S.; Gu, Jie; Feng, Zekun; DiFrancesco, Robin; Morse, Gene D.; Ma, Qing.

In: Current Vascular Pharmacology, Vol. 14, No. 3, 01.05.2016, p. 280-287.

Research output: Contribution to journalArticle

Bednasz, C, Luque, AE, Zingman, BS, Fischl, MA, Gripshover, BM, Venuto, CS, Gu, J, Feng, Z, DiFrancesco, R, Morse, GD & Ma, Q 2016, 'Lipid-lowering therapy in HIV-infected patients: Relationship with antiretroviral agents and impact of substance-related disorders', Current Vascular Pharmacology, vol. 14, no. 3, pp. 280-287.
Bednasz, Cindy ; Luque, Amneris E. ; Zingman, Barry S. ; Fischl, Margaret A. ; Gripshover, Barbara M. ; Venuto, Charles S. ; Gu, Jie ; Feng, Zekun ; DiFrancesco, Robin ; Morse, Gene D. ; Ma, Qing. / Lipid-lowering therapy in HIV-infected patients : Relationship with antiretroviral agents and impact of substance-related disorders. In: Current Vascular Pharmacology. 2016 ; Vol. 14, No. 3. pp. 280-287.
@article{4b31e0fe1ae04f4195cabfa4161439bd,
title = "Lipid-lowering therapy in HIV-infected patients: Relationship with antiretroviral agents and impact of substance-related disorders",
abstract = "Background: The use of combination antiretroviral therapy (cART) has significantly decreased the morbidity and mortality associated with human immunodeficiency virus (HIV) infection. Lipid disorders, including lipodystrophy, hypertriglyceridemia, and hypercholesterolemia, remain the most commonly reported metabolic disorders among those treated with long-term cART. Mounting evidence suggests an association between drug abuse and poor glycemic control and diabetes complications. Substance related disorders (SRD) may increase the risk of metabolic syndrome. Materials and Methods: The aim of this retrospective cohort study was to examine the relationship between SRD, cART, and lipid-lowering agent use in an HIV infected population. Patients received efavirenz or protease inhibitor-based cART for at least 6 months. Prescription information was retrieved from the medical records. The primary outcome was the use of lipid-lowering agents including statins, fibrates and fish oil. The impact of SRD and cART was assessed on the lipidlowering agent use. Results: A total of 276 subjects with HIV infection were included, 90 (33{\%}) received lipid-lowering agents, and 31 (34{\%}) had SRD. Smoking was prevalent among subjects with SRD (84 vs 15{\%}, p",
keywords = "Dyslipidemia, Fibrates, HIV, Lipid-lowering therapy, Metabolic disorder, Statins, Substance-related disorders",
author = "Cindy Bednasz and Luque, {Amneris E.} and Zingman, {Barry S.} and Fischl, {Margaret A.} and Gripshover, {Barbara M.} and Venuto, {Charles S.} and Jie Gu and Zekun Feng and Robin DiFrancesco and Morse, {Gene D.} and Qing Ma",
year = "2016",
month = "5",
day = "1",
language = "English (US)",
volume = "14",
pages = "280--287",
journal = "Current Vascular Pharmacology",
issn = "1570-1611",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Lipid-lowering therapy in HIV-infected patients

T2 - Relationship with antiretroviral agents and impact of substance-related disorders

AU - Bednasz, Cindy

AU - Luque, Amneris E.

AU - Zingman, Barry S.

AU - Fischl, Margaret A.

AU - Gripshover, Barbara M.

AU - Venuto, Charles S.

AU - Gu, Jie

AU - Feng, Zekun

AU - DiFrancesco, Robin

AU - Morse, Gene D.

AU - Ma, Qing

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Background: The use of combination antiretroviral therapy (cART) has significantly decreased the morbidity and mortality associated with human immunodeficiency virus (HIV) infection. Lipid disorders, including lipodystrophy, hypertriglyceridemia, and hypercholesterolemia, remain the most commonly reported metabolic disorders among those treated with long-term cART. Mounting evidence suggests an association between drug abuse and poor glycemic control and diabetes complications. Substance related disorders (SRD) may increase the risk of metabolic syndrome. Materials and Methods: The aim of this retrospective cohort study was to examine the relationship between SRD, cART, and lipid-lowering agent use in an HIV infected population. Patients received efavirenz or protease inhibitor-based cART for at least 6 months. Prescription information was retrieved from the medical records. The primary outcome was the use of lipid-lowering agents including statins, fibrates and fish oil. The impact of SRD and cART was assessed on the lipidlowering agent use. Results: A total of 276 subjects with HIV infection were included, 90 (33%) received lipid-lowering agents, and 31 (34%) had SRD. Smoking was prevalent among subjects with SRD (84 vs 15%, p

AB - Background: The use of combination antiretroviral therapy (cART) has significantly decreased the morbidity and mortality associated with human immunodeficiency virus (HIV) infection. Lipid disorders, including lipodystrophy, hypertriglyceridemia, and hypercholesterolemia, remain the most commonly reported metabolic disorders among those treated with long-term cART. Mounting evidence suggests an association between drug abuse and poor glycemic control and diabetes complications. Substance related disorders (SRD) may increase the risk of metabolic syndrome. Materials and Methods: The aim of this retrospective cohort study was to examine the relationship between SRD, cART, and lipid-lowering agent use in an HIV infected population. Patients received efavirenz or protease inhibitor-based cART for at least 6 months. Prescription information was retrieved from the medical records. The primary outcome was the use of lipid-lowering agents including statins, fibrates and fish oil. The impact of SRD and cART was assessed on the lipidlowering agent use. Results: A total of 276 subjects with HIV infection were included, 90 (33%) received lipid-lowering agents, and 31 (34%) had SRD. Smoking was prevalent among subjects with SRD (84 vs 15%, p

KW - Dyslipidemia

KW - Fibrates

KW - HIV

KW - Lipid-lowering therapy

KW - Metabolic disorder

KW - Statins

KW - Substance-related disorders

UR - http://www.scopus.com/inward/record.url?scp=84964004953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964004953&partnerID=8YFLogxK

M3 - Article

C2 - 26733388

AN - SCOPUS:84964004953

VL - 14

SP - 280

EP - 287

JO - Current Vascular Pharmacology

JF - Current Vascular Pharmacology

SN - 1570-1611

IS - 3

ER -